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Background: Incretin glucagon-like peptide-1 (GLP-1) is a hormone released from cells in the 
gastrointestinal tract (GI), leading to glucose-dependent insulin release from the pancreas. It also 
suppresses postprandial hyperglycemia, glucagon secretion and slows gastric emptying. Exenatide 
(EXE), a functional analog of human GLP-1, was approved by the US FDA in April 2005.
Objective: This article reviews current primary literature on the clinical efficacy and safety 
of EXE in the treatment of type 2 diabetes mellitus (DM) and describes the pharmacokinetics, 
pharmacodynamics, dosing and administration of EXE.
Methods: English-language articles were identified through a search of MEDLINE (1966 to 
March 2009), International Pharmaceutical Abstracts (1970 to present), and Cochrane Database 
of Systemic Reviews (1995 to March 2009). Search terms included EXE, diabetes mellitus, post-
prandial hyperglycemia, gastric emptying, glucagon, pharmacokinetics and pharmacodynamics. 
Articles were selected for review if their designs were randomized, blinded and of controlled 
design that focused on clinical outcomes of patients with type 2 DM.
Results: EXE is administered subcutaneously in the thigh, abdomen or upper arm within the 
60-minute period before the morning and evening meals. Its Cmax is reached within 2.1 hours, 
and its T1/2 in 2.4 hours. EXE’s metabolism is primarily through the kidneys. For the patients 
who received EXE 10 µg SC BID in three, 30-week, placebo-controlled studies with background 
sulfonylureas (SUs), metformin (MET), or SU + MET, there were significant reductions in 
HbA1c (0.77 to 0.86%), fasting plasma glucose (0.6 mmol/L) and body weight (1.6 to 2.8 kg) 
(P  0.05 vs PCB) that were sustained in patients who completed two open-label phase trials 
with an additional 52 weeks of therapy. The use of thiazolidinediones was associated with a 
slight advantage over EXE in improving HbA1c along with increased weight gain; those who 
received EXE lost weight, but experienced more GI adverse effects. Patients who received EXE 
lost significant body weight while patients who received insulin gained weight. Patients receiving 
insulin had lower fasting, prelunch and predinner glucose excursions while patients in the EXE 
groups had lower postprandial glucose levels. Nausea was most frequently (>20%) reported in 
patients receiving the highest dose of EXE (10 µg SC BID vs 5 µg SC BID).
Conclusions: EXE at the dose of 10 µg SC BID has been proven to decrease HbAlc by 
1.3% ± 0.1% and decrease body weight by up to 5.3 ± 0.8 kg at week 82. Nausea was the most 
frequently reported adverse event (.20%) especially in patients being treated with EXE 10 µg 
SC BID. EXE can be safely added to MET therapy, SU therapy or MET + SU combination to 
effectively target glycemic goals in patients with type 2 DM. Long-term, head-to-head studies 
assessing the effect of the EXE ± oral agents/insulins in patients with HbAlc  10% are still 
needed to fully clarify the role of EXE in poorly controlled patients with type 2 DM.
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Introduction
Diabetes mellitus (DM) comprises a group of chronic meta-
bolic disorders characterized by hyperglycemia as a result of 
complete lack of insulin, a relative lack of insulin or insulin 
resistance. DM may result in long-term microvascular (ie, 
retinopathy and nephropathy), macrovascular (ie, cardiovas-
cular disease) and neuropathic complications. In the US, it is 
estimated that 23.6 million people (7.8% of the population) 
have diabetes with the highest prevalence among American 
Indians/Alaska Natives (16.5%), African Americans (11.8%), 
and Hispanics (10.4%).1 The increased cardiovascular risk 
associated with DM contributes to it being the sixth leading 
cause of death in the US.1 For every 1% increase in glycosyl-
ated hemoglobin (HbA1c) above 5%, there is a 20% epidemio-
logical increase in cardiovascular risk.2 The financial impact of 
DM in 2007 was estimated to be US$174 billion (direct medi-
cal costs and indirect costs resulting from lack of employee 
productivity).3 Worldwide, the total number of people with 
DM is projected to increase from 171 million in 2000 to 366 
million in 2030.4 These statistics suggest that the “diabetes 
epidemic” is real and there is an important need to allocate 
resources to educate patients about prevention, lifestyle modi-
fications, and proper usage of diabetes medications.
The prevention of health complications associated 
with DM through effective glucose control (HbA1c  7) 
continues to be the primary objective of DM management.5 
The treatment of type 2 DM consists of life-style changes 
(diet and exercise) and the use of oral hypoglycemic agents, 
insulin sensitizers, oral agents that impede hepatic production 
of glucose, and exogenous insulin.6–8 However, hypoglycemia, 
gastrointestinal (GI) side effects, weight gain, and lack of 
optimal control of postprandial glucose are limitations that 
may present with the use of these type 2 DM treatments, 
preventing patients from reaching glycemic control.9 As a 
result, there is an interest in therapies that control blood 
glucose by alternative physiological mechanisms that do not 
significantly change patients weight, induce hypoglycemia or 
GI side effects,9 In April of 2005, the FDA approved exenatide 
(EXE) as the first incretin mimetic injection formulation to 
treat type 2 DM. This article compiles results of recently 
published primary literature on the efficacy and safety of EXE 
injection. Additional topics discussed in this article include 
dosing, administration, drug interactions, pharmacokinetics, 
and pharmacodynamics of EXE injection.
Materials and methods
English-language articles were identified through a search of 
MEDLINE (1966 to March 2009), International Pharmaceutical 
Abstracts (1970 to present), and Cochrane Database of 
Systemic Reviews (1995 to March 2009). Search terms 
included EXE, diabetes mellitus, postprandial hypergly-
cemia, gastric emptying, glucagon, pharmacokinetics and 
pharmacodynamics. Articles were selected for review 
if their designs were randomized, blinded (investigator, 
participant or both), and of controlled design that focused 
in clinical outcomes of patients with type 2 DM by measur-
ing HbA1c.
Pathophysiology  
of diabetes mellitus
The primary defect in type 1 DM is the absolute lack of insulin 
production that results from cellular-mediated autoimmune 
destruction of pancreatic β-cells. The presence of human 
leukocyte antigens, islet cell antibodies, insulin antibodies 
and/or glutamic acid decarboxylase autoantibodies 
are strong predictors for the development of type 1 DM.6 
Signs and symptoms of hyperglycemia are present when most 
patients have lost 90% of the β-cell function. The treatment 
of type 1 DM includes the use of exogenous insulin, diet 
and exercise.6
The primary defects in type 2 DM are pancreatic β-cell 
failure, increased insulin resistance and impaired insulin 
secretion that leads to relative insulin deficiency.6,7 Insulin 
resistance occurs significantly in skeletal muscle and liver. 
The combination of poor glucose uptake by the tissues 
and continuous production of glucose by the liver during 
the ingestion of glucose (fed state) leads to elevations 
in blood glucose levels. Impaired insulin secretion with 
progressive loss of pancreatic β-cells functioning leads 
to hyperglycemia and lack of sufficient first-phase insulin 
response to signal the liver to stop producing glucose during 
the fed state.6 Other anomalies found in patients with type 2 
DM include the excessive production of glucagon (a hormone 
produced by the pancreas responsible for carbohydrate 
metabolism) and impaired incretin hormones response 
(hormones responsible for stimulating insulin secretion in 
the presence of glucose).10,11 The lack of suppression of 
postprandial glucagon secretion in patients with type 2 DM 
is the result of impaired glucose sensing by pancreatic α-cells 
(cells responsible for the pancreatic secretion of glucagon) 
and/or resistance of pancreatic α-cells to the inhibitory 
actions of insulin.12 Glucagon excess in patients with type 2 
DM counteracts the action of insulin on glucose metabolism 
by stimulating glycogenolysis and gluconeogenesis.10,11
Incretins are gut hormones that are released from 
cells in the GI track within minutes after eating, leading Drug Design, Development and Therapy 2009:3 221
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to glucose-dependent insulin release from the pancreas 
into the blood. There are two incretin hormones known 
as glucose-dependent insulinotropic peptide (GIP) and 
glucagon-like peptide-1 (GLP-1). In type 2 DM, GIP no 
longer modulates glucose-dependent insulin secretion and 
there are modest but significant reductions in meal-stimulated 
circulating levels of GLP-1.13,14 EXE is a functional analog 
of human GLP-1 that binds to and stimulates GLP-1 
receptors, thus increasing insulin secretion. Mechanisms 
by which EXE improves glycemic control include the 
regulation of glucose-dependent insulin secretion, the 
suppression of inappropriately high glucagon secretion, 
the slowing of gastric emptying (which reduces the rate at 
which meal-delivered glucose appears in the circulation) 
and the reduction of food intake.15 Other EXE glycemic 
regulatory properties include the effects on increasing β-cell 
proliferation and inhibition of β-cell apoptosis seen primary 
in animal and small human studies.16–19
Exenatide injection
EXE is approved as an adjunctive subcutaneous therapy to 
improve glycemic control in patients with type 2 DM who 
have not achieved adequate glycemic control while taking 
metformin, a sulfonylurea, a thiazolidinedione, or a combi-
nation of these oral agents.20 EXE is derived from salivary 
secretions of the lizard Heloderma suspectum and shares 
53% amino acid sequence identity with human GLP-1 that 
allows the direct binding to GLP-1 receptors. The in vivo 
potency of EXE has been shown to be much greater than 
that of GLP-1 due to EXE’s resistance to degradation 
by dipeptidyl peptidase-IV (enzyme responsible for de-
activating incretin hormones).21
Pharmacokinetics
EXE reaches median peak plasma concentrations in 2.1 hours 
after subcutaneous injection. The mean peak EXE concentra-
tion (Cmax) is 211 pg/mL and the mean area under the plasma 
concentration-time curve from time zero to infinity (AUC0–inf) 
is 1036 pg*h/mL following subcutaneous administration of 
a 10 µg dose of EXE. The EXE exposure (AUC) increases 
proportionally over the therapeutic dose range of 5 µg to 
10 µg unlike the Cmax values that increase less proportionally 
over the same dose range. No differences in EXE exposure 
are found at the different sites of subcutaneous administration 
(abdomen, thigh, or arm). EXE is predominantly elimi-
nated by glomerular filtration with subsequent proteolytic 
degradation. The t1/2 of EXE is 2.4 hours. These pharmacoki-
netic characteristics of EXE are independent of the dose.20
Special populations
No pharmacokinetic studies were identified that assessed 
the effect of race, gender, age, weight or hepatic insufficiency 
on the pharmacokinetics of EXE. However, in patients 
with end-stage renal disease that are receiving dialysis, 
mean EXE clearance is reduced to 0.9 L/h compared with 
9.1 L/h in healthy subjects.20 In a study by Linnebjerg et al22 
the effects of renal impairment on the pharmacokinetics 
of a single EXE dose (5 and 10 µg) administered 15 min 
prior to a standardized breakfast in patients classified as 
having normal renal function (Cockcroft-Gault creatinine 
Table 1 exenatide characteristics20,51
indication Adjunctive therapy in patients with type 2 diabetes who have not reached glycemic goals despite receiving 
treatment with metformin, sulfonylurea, a thiazolidinedione or a combination of these oral agents
Mechanism of action Regulates glucose-dependent insulin secretion, suppresses inappropriately high glucagon secretion, slows down gastric 
emptying (reduces the rate at which meal-delivered glucose appears in the circulation) and reduces food intake
Dosage and administration Starting dose = 5 µg
Target dose = 5 or 10 µg
Route of administration = subcutaneous injection in the thigh, abdomen or upper arm
Frequency and timing of administration = twice daily within the 60-min period before the morning and evening 
meals (or before the two main meals of the day, approximately 6 hours or more apart)
Adverse events Gastrointestinal = nausea, vomiting, diarrhea, pancreatitis (rare)
Hypoglycemia (especially in patients taking sulfonylurea concomitantly)
Other properties Pregnancy category C (there are no adequate and well-controlled studies in pregnant women)
Suppresses appetite
Patients may lose weight
Caution should be exercised in patients with impaired renal function
Cost Average wholesale price: 
1.2 mL (5 µg/0.2 mL) prefilled pen = US$240.84
2.4 mL (10 µg/0.4 mL) prefilled pen = US$282.63Drug Design, Development and Therapy 2009:3 222
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clearance [CrCl] . 80 mL/min, N = 8), mild renal 
impairment (CrCl 51 to 80 mL/min, N = 8), moderate renal 
impairment (CrCl 31 to 50 mL/min, N = 7) or end stage 
renal disease (ESRD, patients receiving hemodialysis for 
at least 1 month before screening, N = 8) were evaluated.
From the 31 participants (16 out of 31 were male), only 
one subject had type 2 DM that was controlled with diet. 
All patients in the normal renal function group (mean [±SD] 
age, 46 [5.5] years; mean BMI, 25.7 [4.08] kg/m2; mean 
[range] CrCl, 111 mL/min [83 to 156]) and in the mild renal 
impairment group (mean [±SD] age, 56 [9.9] years; mean 
BMI, 25.5 [2.77] kg/m2; mean [range] CrCl, 68 mL/min 
[60 to 78]) received a single dose of EXE 10 µg. Five out 
of the 7 patients with moderate renal impairment (mean 
[±SD] age, 64 [9.6] years; mean BMI, 27.2 [3.02] kg/m2; 
mean [range] CrCl, 45 mL/min [34 to 50]) and all 8 patients 
with ESRD (mean [±SD] age, 52 [18.3] years; mean BMI, 
23.7 [3.29] kg/m2) received a single dose of EXE 5 µg. After 
investigators combined the data from this small sample size 
study with previously available data from 4 single-dose 
crossover studies, researchers found that compared with 
participants in the normal renal function group: 1) EXE 
clearance was significantly reduced by 36% in the moderate 
renal impairment group (least squares geometric mean 
[CLp/F], 8.14 vs 5.19 L/h, P = 0.008) and by 84% in the 
ESRD group (8.14 vs 1.3 L/h P  0.001); 2) EXE AUC∞-⊥ 
significantly increased 1.63 times (P = 0.003) in the moderate 
renal impairment group and 6.24 times (P  0.001) in the 
ESRD group; 3) EXE Cmax significantly increased 3.28 times 
(P  0.001) in the ESRD group and 4) antiemetic medica-
tions were administered to 7 out of 8 participants with ESRD 
because severe or longer duration nausea compared with 
1 out of 8 participants in the normal renal function group.22 
The manufacture of EXE recommends caution when using 
EXE in patients with ESRD secondary to changes in the 
pharmacokinetics of EXE and decrease tolerability.20
Drug interactions
EXE slows gastric emptying and therefore may reduce the 
rate of absorption of certain oral medications. Patients should 
be advised to take medications that depend on threshold 
concentrations for efficacy (ie, oral contraceptives and 
antibiotics) at least 1 hour before injecting EXE. Additionally, 
caution should be exercised when taking medications that 
require rapid GI absorption while using EXE.20
In a randomized, single-blind, placebo-controlled, 6-way 
crossover study by Blase et al23 the effects of EXE 10 µg 
on the pharmacokinetics of acetaminophen 1000 mg were 
assessed (N = 39 healthy subjects). Acetaminophen AUC0–12 h 
levels were reduced by 11% to 24% and acetaminophen Cmax 
were reduced by 37% to 56% depending on the coadminis-
tration times with EXE (–1, 0, +1, +2 and +4 hours).
In an open-label study by Kothare et al24 the effects of 
EXE 10 µg twice daily (BID) on the steady-state pharma-
cokinetics of oral digoxin (0.5 and 0.25 mg) were assessed 
(N = 21 healthy male subjects). A 17% reduction of digoxin 
Cmax was noted. However, peak concentrations of digoxin 
remained within the therapeutic concentration range.
In an open-label, 2-period, fixed-sequence study 
by Soon et al25 the effects of EXE 10 µg BID on the 
pharmacokinetic and pharmacodynamics of warfarin 
25 mg one-time dose (N = 16 healthy subjects) were 
evaluated. When comparing R-warfarin + EXE with 
R-warfarin alone, EXE did not significantly alter the AUC0–inf 
(110, 425 h⋅ng/mL vs 99,411 h⋅ng/mL) or Cmax (1345 ng/mL vs 
1282 ng/mL) of warfarin. No significant alterations were 
found when comparing the maximum-observed International 
Normalized Ratio (INRmax, 1.72 vs 1.95) or time to INRmax 
(24.05 to 48.20 h vs 36.00 to 48.63 h). However, spontaneous 
postmarketing reports have noted increases in INR levels with 
the combined use of warfarin and EXE that in some cases 
had been associated with bleeding.20
Pharmacodynamics
effect on β-cell functioning 
and insulin secretion
Bunck et al26 conducted a 52-week, randomized study in 
Sweden, Finland and the Netherlands to assess the effects 
of EXE (N = 36; mean [±SD] age, 58.4 [1.4] years; mean 
weight, 90.6 [2.1] kg; mean HbA1c, 7.6% [0.1%]) and 
insulin glargine (N = 33; mean [±SD] age, 58.3 [1.3] years; 
mean weight, 92.4 [2.4] kg; mean HbA1c, 7.4% [0.1%]) 
on type 2 DM patients’ β-cell function, glycemic control, 
body weight and safety. Patients randomized to EXE 
received an initial dose of 5 µg BID, injected 15 min 
before breakfast and dinner for 4 weeks and 10 µg BID 
for the remaining 48 weeks of  the study. For patients in 
the EXE group with HbA1c 7.1% to 7.5% in 2 consecutive 
visits or HbA1c  7.6% at any visit, EXE was titrated to a 
maximum dose of 20 µg TID. Patients randomized to insu-
lin glargine were started with 10 units at bedtime and were 
instructed to titrate dose upward or downward based on 
their self-monitored blood glucose levels and pre-specified 
algorithm. Insulin secretion and sensitivity was measured 
during a combined euglycemic–hyperinsulinemic and Drug Design, Development and Therapy 2009:3 223
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hyperglycemic clamp procedures using arginine prior to 
randomization, followed by 52 weeks of active therapy 
and a 4-week off therapy period. After 52 weeks of EXE 
treatment, C-peptide secretion in response to 15 mmol/L 
of glucose (nmol*min/L) at phase 1 (mean difference 
between groups, AUC180–190 min = 1.53 ± 0.11) and phase 2 
(mean difference between groups, AUC190–260 min = 2.85 ± 0.22) 
were statistically significantly greater than in the insulin 
glargine group, P  0.0001. Similarly, in the EXE group, 
the C-peptide response to arginine (mean difference 
AUC260–270 min = 2.46 ± 0.20) at 15 mmol/L of glucose concen-
tration (nmol⋅min/L) was statistically significantly greater 
than in the insulin glargine group, P  0.0001.
Fehse et al27 evaluated the effects of  EXE  (bolus  =  50 ng/min 
for 30 min and 25 ng/min for 270 min) on insulin, C-peptide 
and plasma glucagon secretions in patients with type 2 DM. 
Thirteen patients with type 2 DM underwent two experi-
ments: 1) saline infusion on day 2; and 2) IV EXE on day 4 
(mean [±SD] age, 56 [7] years; mean BMI, 31.7 [2.4] kg/m2; 
mean HbA1c, 6.6% [0.7%]). Ten healthy patients (control) 
received saline IV on day 2 (mean [±SD] age, 57 [9] years; 
mean BMI, 32 [3] kg/m2). All oral anti-glycemic agents were 
held during the study duration. An insulin infusion (or saline 
in the control group) was administered before the EXE 
infusion in order to maintain the experimental group (type 2 
DM patients) with fasting plasma glucose readings of 79 to 
101 mg/dL. The IV infusion of EXE was started at 10:00 h 
(after 240 min of the insulin infusion and 180 min before 
the glucose bolus infusion) and the glucose bolus (0.3 g/kg 
body weight as 50% glucose in water) was administered at 
the 13:00 h. Significantly higher plasma insulin AUC0–10 min, 
AUC10–120 min and AUC0–120 were observed during the EXE 
infusion in type 2 DM patients (655 ± 116, 6923 ± 941, 
7623 ± 1040 mU⋅min/L) compared with the saline infusion 
in the same type 2 DM patients (212 ± 38, 2611 ± 355, 
2830 ± 386 mU⋅min/L), P  0.0001. Similarly, a significantly 
higher C-peptide concentration AUC0–10 min, AUC10–120 min 
and AUC0–120 were observed during the EXE infusion (52 ± 6, 
908 ± 65, 961 ± 70 ng⋅min/L) compared with the saline 
infusion (26 ± 3, 514 ± 37, 541 ± 39 ng⋅min/L), P  0.0001. 
Comparable suppression on plasma glucagon concentrations 
was observed while patients with type 2 DM were receiving 
EXE and saline (no statistical differences were noted).
effect on postprandial glucose 
and glucagon levels
Linnebjerg et al28 conducted a randomized, placebo-controlled, 
open-label, six-way crossover study to assess the effect 
of EXE 10 µg subcutaneous injection timing (-60, -15, 
0, +30 and +60 min) vs placebo (-15 min) relative to a 
standardized breakfast meal on postprandial glucose level in 
patients with type 2 DM during 6 consecutive days. Eighteen 
patients (mean [±SD] age, 58 [6.3] years; mean BMI, 29.2 
[3.64] kg/m2; mean HbA1c, 6.8% [0.6%] and fasting plasma 
glucose, 8.6 [1.4] mmol/L) receiving oral glucose lowering 
agents were enrolled in the study. Compared to placebo, there 
was an overall reduction in postprandial glucose AUC0-6 h, 
Cmax, Cmin and insulin excursions in patients that received 
premeal EXE at -60, -15, and 0 min (Table 2). The lowest 
glucose concentrations were measured 150 min after the meal 
(4.4 mmol/L). Inversely, high peak plasma glucose excur-
sions were observed in patients that received EXE postmeal 
(+30 and +60), which were only 21% and 11% lower than 
placebo, respectively (Table 2).
In a study conducted by Cervera et al29 the effects 
of intravenous (IV) EXE on insulin secretion, glucagon 
suppression, postprandial hyperglycemia and gastric 
emptying (using acetaminophen 1000 mg dose) were 
evaluated in 12 patients with type 2 DM taking oral glucose 
lowering agents and eating a standardized meal (mean 
[±SD] age, 44 [2] years; mean BMI, 34.1 [4] kg/m2; mean 
HbA1c, 7.5% [1.5%] and duration of diabetes, 6.6 [3.5] 
years). The patients participated in a 3-phase, 6-hour 
mixed-meal tolerance test conducted 2 to 4 weeks apart: 
phase 1) intravenous saline infusion during the meal 
(control); phase 2) IV EXE (0.05 µg/min) started 15 min 
before the meal and decreased to 0.025 µg/min 45 min after 
the meal ingestion and phase 3) IV EXE + IV glucagon 
administered at a rate estimated to match the plasma 
glucagon level during the saline control phase (phase 1). 
There was an overall statistically significant reduction in 
fasting plasma glucose, plasma insulin, C-peptide and 
glucagon secretion the IV EXE phase compared to the 
control phase (Table 3). Additionally, the total rate of plasma 
glucose appearance after the ingestion of the standardized 
meal over the 360-min period was significantly attenuated 
in the IV EXE (212 ± 6 mg/min) and significantly reduced 
in the IV EXE + IV glucagon phase (271 ± 13 mg/min) 
compared with control (379 ± 30 mg/min), P  0.05. 
Endogenous glucose remained unchanged during the control 
phase, however, it was significantly reduced by 40% in the 
IV EXE phase and by 20 % in the IV EXE + glucagon 
phase, P  0.01. Lastly, in the IV EXE phase, there was a 
58% significant reduction in mean acetaminophen plasma 
concentration when compared with the control phase 
(840 ± 135 vs 1995 ± 270 µg/mL, P  0.001).Drug Design, Development and Therapy 2009:3 224
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Kolterman et al30 conducted 2 simultaneous studies 
(A and B) to evaluate the effects of EXE on postprandial 
glucose levels after using EXE (0.1 µg/kg) SC BID for 5 days 
(study A) and on glucose levels after an overnight fast using 
3 different doses of EXE SC 3 times per day (0.05 µg/kg, 
0.1 µg/kg and 0.2 µg/kg, study B) in patients with type 2 
DM.
Study A was a single blind, placebo-controlled, 
two-period crossover study with 24 patients with type 2 
DM assigned to 4 groups: 1) diet management alone; 
2) oral anti-diabetic agent (OAA) + HbA1c  8%); 
3) OAA + HbA1c  8% to 12%; 4) insulin ± OAA and 
HbA1c  12% (mean [±SD] age, 55.8 [2.1] years; mean 
BMI, 28.8 [0.8] kg/m2; mean weight, 82.9 [3.3] kg). Each 
dose of EXE was injected subcutaneously before breakfast 
and dinner. Postprandial glucose was significantly reduced 
during the 300 min postadministration of EXE (Table 4). 
Postprandial insulin elevations were reduced significantly 
in the patients that received EXE on day 5 compared with 
placebo (35% reduction, P = 0.0011). Data for postprandial 
plasma insulin concentrations for the placebo or EXE 
group on day 1 were not provided. Compared to placebo, 
postprandial glucagon concentrations in patients receiving 
EXE were significantly lower and relatively unchanged from 
baseline concentrations (P = 0.0123) (Table 4).
Study B was a double blind, placebo-controlled, 
4-period crossover study with 13 patients (mean [±SD] 
age, 49.0 [2.0] years; mean BMI, 32.8 [1.6] kg/m2; mean 
weight, 90.6 [5.1] kg) assigned received a single dose 
of EXE (0.05 µg/kg, 0.1 µg/kg, 0.2 µg/kg) and placebo 
on days 1, 3, 5 and 7 (1-day wash-out period between 
treatments). Besides EXE treatment, patients were treated 
Table 2 Postprandial glucose excursions in patients with type 2 diabetes mellitus treated with exenatide at various time points relative 
to a standardized meal28
Placebo Exenatide 10 µg
  -15 min -60 min -15 min 0 min +30 min +60 min
Postprandial incremental plasma glucose  
AUC0–6 h (mmol/L∙min)†
311 
(124, 499)
-426 
(-618, -234)
-402 
(-590, -215)
-418 
(-610, -227)
-275 
(-463, -87)
-299 
(-486, -111)
incremental plasma glucose  
C0–6 h max (mmol/L)*
5.81 
(5.06, 6.56)
1.41 
(0.63, 2.18)
1.54 
(0.79, 2.30)
1.88 
(1.10, 2.66)
4.57 
(3.82, 5.33)
5.19 
(4.43, 5.94)
incremental plasma glucose  
C0–6 h min (mmol/L)†
-2.33 
(-2.73, -1.93)
-3.22 
(-3.63, -2,81)
-3.51 
(-3.91, -3.10)
-3.82 
(-4.23, -3,40)
-4.06 
(-4.47, -3.66)
-4.35 
(-4.75, -3.95)
incremental plasma insulin**  
C0–6 h max (pmol/L)
439.3 
(344.2, 560.7)
217 
(169.1, 278.4)
263.4 
(206.4, 336.21)
268.4 
(209.2, 344.32)
529.3 
(414.7, 675.53)
526.0 
(412.2, 671.07)
Note: Data are estimates (95% Ci).
†P  0.05 vs placebo; *P  0.05 vs placebo not including plasma glucose Cmax for exenatide 10 µg at + 60 min; **P  0.05 vs placebo not including plasma insulin Cmax for 
exenatide 10 µg at +30 min and +60 min.
Abbreviation: AUC, area under the concentration time curve.
Table 3 effects of intravenous exenatide on glucose homeostasis and regulatory markers in patients with type 2 diabetes mellitus29
   Control 
(Phase 1)
IV EXE 
(Phase 2)
IV EXE + IV glucagon 
(Phase 3)
Postprandial plasma glucose  
AUC0–360 min (mg/dL)†
196 (9) 127 (8) 152 (7)
Postprandial plasma insulin  
AUC0–360 min (pmol/L)†
99 (12) 179 (20) 190 (17)
Postprandial plasma C-peptide  
AUC0–360 min (pg/mL)†
7.4 (0.8) 12.4 (0.9) 16.9 (0.8)
Postprandial plasma glucagon  
AUC0–360 min (pg/mL)*
79 (6) 67 (7) 74 (4)
Rate of endogenous glucose mg/min†**  
AUC0–360 min (mg/min)
249 (19)  142 (12)  209 (12) 
Note: Data are mean (±SD).
†P  0.05, iv eXe and iv eXe + iv glucagon vs control; *P  0.05, iv eXe vs control; **P  0.05, iv eXe vs iv eXe + iv glucagon.
Abbreviations:   AUC, area under the concentration time curve; eXe, exenatide.Drug Design, Development and Therapy 2009:3 225
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with diet alone, metformin alone, a thiazolidinedione 
alone, or a combination of metformin + thiazolidinedi-
one. Patients ingested acetaminophen (20 mg/kg) at the 
time of consuming the standardized meal to assess gastric 
emptying. Compared to placebo: 1) fasting plasma glucose 
levels were reduced during the 8 hour period of observation 
(Table 4, P  0.0001); 2) fasting serum insulin concentra-
tions increased in a dose-depend manner during the first 
3 hours postadministration of EXE (Table 4, P  0.0001); 
3) fasting plasma glucagon concentrations were sup-
pressed although it did not reach statistical significance and 
4) rate of acetaminophen plasma concentration exposure 
was reduced by EXE 0.1 µg/kg compared with placebo 
significantly (AUC180 min, mean [±SD]; 25.8 [3.0] µmol/L 
vs 82.8 [5] µmol/L, respectively).
effect on gastric emptying and food intake
Linnebjerg et al31 evaluated the effects of EXE on 
gastric emptying and appetite perception in patients 
with type 2 DM (N = 17) in a randomized, single blind, 
3-period crossover study (mean [±SD] age, 57 [10.1] years; 
mean BMI, 29.2 [3.6] kg/m2; mean HbA1c, 8.5% [1.1%]; 
duration of diabetes, 6.7 [4.5] years and fasting serum 
glucose, 9.7 [3.5] mmol/L). Patients received 15 min prior 
to breakfast or dinner 5 µg of EXE SC BID, EXE 10 µg 
SC BID or placebo for 3 periods of 5 days each. Fifteen 
minutes after the morning dose on day 5, patients were 
instructed to eat a standardized solid and liquid meal within 
10 min of the administration of either placebo or EXE. 
Gastric empting was assessed by scintigraphy and appetite 
suppression with a visual analog scale (VAS). Compared 
with placebo, EXE significantly slowed gastric emptying 
(T50) for solid and liquid meals (solid T50, 90% confidence 
interval [CI]; placebo, 60 [50–70] min; EXE 5 µg, 111 
[94–132] min; EXE 10 µg, 169 [143–201] min; liquid T50; 
placebo, 34 [25–46] min; EXE 5 µg, 87 [65–117] min; 
EXE 10 µg, 114 [85–154] min) P  0.01, respectively. 
EXE reduced postprandial glucose compared with placebo 
(mean AUC0–6 hours [coefficient variation, CV] placebo, 
60 [29.2] mmol*h/mL; 5 µg, 45.4 [30.8] mmol*h/mL; 
10 µg, 41.4 [24.5] mmol*h/mL, P  0.01). EXE reduced 
postprandial Cmax (mean Cmax [coefficient variation, CV] 
placebo, 13.9 [22.2] mmol/mL; 5 µg, 10.4 [28.8] mmol/mL; 
10 µg, 9.62 [19.6] mmol/mL, P  0.01). Patients who 
received EXE 5 µg felt they could eat less (VAS question #4, 
How full do you feel?) 3 to 6 hours after eating the stan-
dardized meals compared with placebo (least squares [LS] 
mean difference [95% CI]; –1.23 [–2.31, –0.15], P = 0.03). 
Table 4 Glucose, insulin and glucagon concentrations following treatment with exenatide in a selected group of patients with type 2 
diabetes mellitus30
Study A (exenatide 0.1 µg/kg SC BID)
Placebo* Exenatide 0.1 µg/kg
  Day 1 Day 5 Day 1* Day 5
Fasting glucose (mg/dL)†  
before meal
174.6* 170.3 (9.1) 176.4 159.5 (10)
Postprandial glucose†  
AUC120 min (mg/dL⋅min)
270* 289 (17) 132.2 140*
Postprandial glucose†  
AUC300 min (mg/dL⋅min)
180* 175.5 (14.9) 136.8 177.8 (14.8)
Postprandial plasma†  
insulin AUC120 min (µg U/mL⋅min)
– 86.3 (28) – 35.9*
Glucagon (pg/mL)†  
180 min after meal
– 122.7 (18.1) – 98.9 (7.2)
Study B (multiple doses of exenatide)
Placebo 0.05 µg/kg 0.1 µg/kg 0.2 µg/kg
Fasting glucose (mg/dL)†  
AUC3 hr (mg/dL⋅min)
195 (13.2) 137.6 (9.4) 120.6 (8.6) 108.9 (6.7)
Fasting serum insulin†  
Cmax(µgU/mL)
0.9 (1.3)  8.8 (1.5)  20.0 (2.9)  25.6 (4.5) 
Note: Data are means (SeM).
†P  0.05 vs placebo; *Data estimated from figures of  30; – data not provided.
Abbreviation: AUC, area under the concentration time curve.Drug Design, Development and Therapy 2009:3 226
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Although a similar perception was found in patients taking 
EXE 10 µg compared with placebo, this difference did 
not reach statistical significance (LS mean difference 
[95% CI]; –1.01 [–2.11, –0.09], P = 0.07).
Meier32 et al evaluated the effects of EXE on insulin 
secretion, postprandial glucose and gastric emptying in 
patients with type 2 DM (N = 12) receiving 3 different infu-
sion rates of EXE (0.4, 0.8 and 1.2 pmol/kg⋅min) or placebo 
in a fasting state and after a solid standardized meal (mean 
[±SD] age, 57 [9] years; mean BMI, 30.2 [5] kg/m2; mean 
HbA1c, 6.8% [1.3%]; duration of diabetes, 4 [1] years and 
waist to hip ratio, 0.95 [0.11]). Under fasting conditions the 
following data were extrapolated from figures, compared to 
placebo: 1) fasting glucose concentrations were significantly 
lowered during the administration of all the EXE infusions 
(360 min post-treatment administration; 150 mg/dL 
[placebo] vs 100 mg/dL [EXE infusions], P  0.001); 
2) insulin and C-peptide concentrations increased 
significantly (120 min post-treatment administration; 
insulin, 10 mU/L [placebo] vs 40 mU/L [EXE 1.2 pmol/
kg*min], P  0.001 and C-peptide, 2 ng/mL [placebo] 
vs 7 ng/mL [EXE 1.2 pmol/kg*min]); and 3) glucagon 
concentrations were not significantly different between 
the placebo group and EXE groups (P = 0.89). After the 
standardized meal test, the EXE 0.8 pmol/kg⋅min and 
1.2 pmol/kg*min groups exhibited a significant reduction 
(p = 0.001) in glucose concentration compared with 
placebo as early as 60 min postingestion (AUC120 min, 
100 mg/dL for both EXE 0.8 and 1.2 pmol/kg⋅min 
groups vs 250 mg/dL placebo, respectively). Placebo 
postprandial insulin concentrations from 60 to 300 min 
were significantly higher (P = 0.0031) than the concen-
trations measured after all dosages of EXE, 0.4, 0.8, and 
1.2 pmol/kg⋅min, 4000 mU/L⋅min vs 2500, 2000 and 
1000 mU/L, respectively. C-peptide secretion from 60 to 
300 min was the highest in the placebo group compared with 
the EXE 1.2 pmol/kg⋅min group (P = 0.0074, 400 ng/mL⋅min 
vs 150 ng/mL.min, respectively). Glucagon secretion was 
suppressed significantly in the EXE groups compared 
with placebo (P  0.001). At 240 min postmeal ingestion, 
gastric emptying was significantly reduced (P  0.001) 
and the initial gastric contents remained in the stomach in 
a dose dependent manner in the EXE groups (0.4, 0.8 and 
1.2 pmol/kg⋅min) compared with placebo; 39% (6%), 56% 
(9%), 74% (9%) vs 26% (3%), respectively.
Toft-Nielsen et al33 conducted a randomized, single 
blind study to assess the effects of EXE SC injection 
(1.2 and 2.4 pmol/kg⋅min) on appetite/satiety and insulin, 
glucose and glucagon concentrations in 10 patients with 
type 2 DM for 48 hours. Four patients received a dose of 
EXE 1.2 pmol/kg⋅min SC once daily for 48 hours (mean 
[±SD] age, 49.3 [2.7] years; mean BMI, 34.3 [3.4] kg/m2; 
mean HbA1c, 9.3% [1.6%]; duration of diabetes, 4.0 [2.1] 
years) and 6 patients received a dose of 2.4 pmol/kg⋅min 
SC BID for 48 hours (mean [±SD] age, 59 [ 2.8] years; 
mean BMI, 34.0 [1.4] kg/m2; mean HbA1c, 8.8% [0.3%]; 
duration of diabetes, 4.1 [2.1] years). All patients were 
instructed to follow a detailed diabetes diet, to use a 
portable infusion pump for treatment delivery and to 
rate sensations of hunger, satiety, fullness, prospective 
food consumption, nausea and overall well-being on 
a VAS of 100 points. Twelve hours after the patients 
received EXE dose 4 pmol/kg*min SC, satiety rates 
significantly increased compared with control (50 vs 40) 
and prospective food consumption significantly decreased 
in the EXE group compared with control (40 vs 60), 
P  0.05 respectively. Similarly, at 18 hours after EXE 
4 pmol/kg⋅min SC, satiety rates significantly increased 
compared with control (100 vs 80) and prospective food 
consumption (0 vs 20) and hunger (0 vs 10) significantly 
decreased, P  0.05 respectively. Additionally, on day 2, 
24-hour mean glucose decreased from 15.4 ± 1.0 (control) 
to 13.0 ± 1.0 mmol/L (EXE, P = 0.0009) and fasting glucose 
decreased from 14.1 ± 0.9 (control) to 12.2 ± 0.7 mmol/L 
(EXE, P = 0.009). Mean insulin levels increased from 
189 ± 40 pmol/L to 224 ± 48 pmol/L (P = 0.03) and mean 
C-peptide levels increased from 2122 ± 312 pmol/L to 
2336 ± 285 pmol/L (EXE, P = 0.0003).
Clinical efficacy and safety
Twice daily monotherapy
Moretto  et al34  conducted  a  24-week,  randomized, 
double-blind, placebo-controlled, parallel-group study to 
determine the efficacy and tolerability of EXE 5 µg or 10 µg 
in treatment-naïve patients with type 2 DM. Patients were 
excluded if they had blood pressures 160/110 mmHg or 
received medications for weight loss within 12 weeks of 
screening. Patients received SC injections of PCB BID 
for 2 weeks and were then randomized to 1 of 3 groups: 
PCB (N = 77, 55% males, mean ± SD age 53 ± 9 years, 
66% White and 27% Asian,) EXE 5 µg BID (N = 77, 52% 
males, 54 ± 10 years of age, 65% White and 29% Asian), 
EXE 10 µg BID (N = 78, 62% males, 55 ± 10 years of age, 
72% White and 23% Asian); those in the EXE 10 µg BID 
group were initiated on 5 µg BID for 4 weeks followed 
by 10 µg BID for 20 weeks. Patients self-administered Drug Design, Development and Therapy 2009:3 227
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treatment SC in the upper arm, thigh, or abdomen 15 min 
before morning and evening meals. The primary endpoint 
was change from baseline in HbA1c at week 24 or last-
observation-carried-forward.
The baseline mean ± SD HbA1c for those in the 
PCB,  EXE  5  µg  and  EXE  10  µg  groups  were  as 
follows: 7.8% ± 0.9%, 7.9% ± 1.0%, and 7.8% ± 1.0%; 
at 24 weeks, the mean change in HbA1c was -0.2% ± 0.1%, 
–0.7% ± 0.1%, and –0.9% ± 0.1%, respectively (P  0.001 
EXE 10 µg vs PCB and P = 0.003 EXE 5 µg vs PCB). A linear 
dose effect indicated more improvement in HbA1c with the 
higher dose of EXE (P = 0.024). At baseline, the fasting 
serum glucose (FSG) was 154 to 166 mg/dL for all groups; 
at 24 weeks, the mean change in FSG was -5.2 ± 4.0 mg/dL, 
-17.5 ± 4.0 mg/dL, and -18.7 ± 4.0 mg/dL, respectively 
(P = 0.016 EXE 10 µg vs PCB and P = 0.029 EXE 5 µg vs 
PCB). At baseline, the weight was 85 to 86 kg for all 
groups; at 24 weeks, the mean change in weight was 
-1.4 ± 0.3 kg, -2.8 ± 0.3 kg, and –3.1 ± 0.3 kg, respec-
tively (P  0.001 EXE 10 µg vs PCB and P = 0.004 EXE 
5 µg vs PCB). Significant changes in weight occurred 
at weeks 8, 12, 16, and 24 in patients randomized to the 
EXE 10 µg vs PCB (P  0.007) and at weeks 16 and 24 
for those in the EXE 5 µg vs PCB groups (P  0.027), 
respectively. Pancreatic β-cell function (determined by 
HOMA-B) increased by 6%, 32% and 28%, respectively 
(P = 0.01 EXE 10 µg vs PCB and P = 0.002 EXE 5 µg 
vs PCB). The most common treatment-emergent adverse 
events reported in 2% of patients in the EXE 5 µg, EXE 
10 µg, and PCB groups were hypoglycemia (n = 4, n = 3 
and n = 1), headache (n = 4, n = 2, and n = 3), influenza 
(n = 3, n = 5, and n = 3), and nausea (n = 2, n = 10, and 
n = 0; P = 0.01 for combined EXE group vs PCB).
Limitations of this study included short duration of 
24 weeks and small sample size as only 66, 68, and 69 patients 
in the EXE 5 µg, EXE 10 µg and PCB groups completed 
the study.
Once weekly monotheraphy
Drucker et al35 conducted a 30-week, randomized, comparator-
controlled, open-labeled, non-inferiority study to determine 
the efficacy and safety of EXE 2 µg sustained-release 
formulation injected SC week (N = 148, 55% males, 83% 
White, mean ± SD age 55 ± 10 years, mean DM duration 
7 ± 6 years) vs EXE 10 µg SC BID (N = 147, 51% males, 
73% White, 55 ± 10 years of age, 6 ± 5 years DM duration). 
Concomitant DM medications included MET (77% vs 60%), 
SUs (37% in both groups), or a thiazolidinedione (TZDs) 
(15% vs 17%), respectively. Patients receiving insulin or any 
agents that altered GI motility were excluded from the study. 
The cutoff value used to determine no difference between 
the treatments was the upper limit of the two-sided 95% CI 
for the difference in HbA1c change was  0.4%. 
At baseline, the mean ± SD HbA1c and weight for all 
patients were 8.3% ± 1.0% and 102 ± 19 kg, respectively. 
At week 30, patients randomized to EXE once weekly group 
vs BID group reported a reduction in HbA1c of -1.9% ± 
0.1% vs -1.5% ± 0.1% (mean difference between the 
groups -0.33% ± 0.1%, 95% CI -0.54 to -0.12), intention-
to-treat (ITT) P = 0.0023. Therefore, EXE once weekly was 
not inferior to 10 µg BID. Overall, 77% vs 61% of patients, 
respectively, reached a target HbA1c  7% (P = 0.0039); 65% 
vs 35% of patients with a baseline HbA1c  9% reached a 
target HbA1c  7% (P = 0.02). Mean ± SE change in fasting 
plasma glucose was -2.3 ± 0.2 mmol/L vs -1.4 ± 0.2 mmol/L, 
95% CI -1.3 to -0.52, ITT P  0.0001, respectively. The 
mean ± SE reduction in weight was -3.7 ± 0.5 kg vs -3.6 ± 
0.5 kg, 95% CI -1.3 to 1.1, ITT P = 0.89. Fifty-one patients 
underwent a meal tolerance test at baseline and at 30 weeks. 
The change from baseline in 2-hour postprandial plasma 
glucose was -6.9 ± 0.5 mmol/L vs -5.3 ± 0.5 mmol/L, 95% 
CI -0.4 to -2.9, P = 0.0124, respectively. At baseline, the 
mean ± SD glucagon levels were 103 ± 3.1 ng/L vs 99.0 ± 
3.0 ng/L; at week 30, the least square mean ± SE glucagon 
reductions were -18.0 ± 2.9 ng/L vs -6.4 ± 2.9 ng/L, 
P  0.05, respectively. 
The most commonly reported AEs reported by 5% of 
those in the EXE once weekly group vs BID group were 
nausea (26.4% vs 34.5%), vomiting (10.8% vs 18.6%), 
injection site pruritus (17.6% vs 1.4%), upper respiratory 
tract infections (8.1% vs 17.2%), diarrhea (13.5% vs 13.1%), 
constipation (10.8% vs 6.2%), injection-site bruising (4.7% 
vs 10.3%), and urinary tract infections (10.1% vs 8.3%), 
respectively. Nine vs 7 patients, respectively, withdrew 
from the study for various reasons. No major episodes of 
hypoglycemia were reported, but in 16 patients receiving 
sulfonylureas, 8 patients in each group complained of minor 
episodes of hypoglycemia, respectively. No episodes of 
pancreatitis were reported.
Efficacy with metformin and sulfonylureas
Three 30-week randomized, triple-blind, placebo-controlled, 
parallel-group studies were conducted to evaluate the effect 
of EXE on glycemic control in patients failing maximally 
effective doses of sulfonylurea monotherapy (SU),36 metformin 
(MET) monotherapy,37 or combination therapy (SU + MET).38 Drug Design, Development and Therapy 2009:3 228
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Patients in the study with background SUs only received one 
of the following: glimepiride 4 mg/day, glipizide 20 mg/day, 
glipizide XL 10 mg/day, glyburide 10 mg/day, micronized 
glyburide 6 mg/day, chlorpropamide 350 mg/day, tolazamide 
500 mg/day.36 Patients in the study with background MET only 
received 1500 mg/day.37 In the study where patients received 
combination therapy, all patients received MET  1500 mg/day 
and SUs; to standardize SU use, patients were randomized 
either to a maximally effective group (MAX group, dosages 
listed above) or minimally effective group (MIN group, at the 
following dosages: glimepiride 1 mg/day, glipizide 5 mg/day, 
glipizide XL 5 mg/day, glyburide 1.25 mg/day, micronized 
glyburide 0.75 mg/day, chlorpropamide 100 mg/day, 
tolazamide 100 mg/day, or tolbutamide 250 mg/day).38 
To address hypoglycemia in patients receiving SU, 50% 
reductions in dose or eventual discontinuation (depending on 
the recurrence of hypoglycemia) in the event of a documented 
episode or two undocumented or suspected episodes were 
allowed.36,38 Patients self-administered placebo (PCB) SC 
twice daily for 4 weeks; after that, those randomized to active 
treatment received another 4 weeks of EXE 5 µg SC BID 
15 min before a meal; then, half of these patients maintained 
their dose of EXE at 5 µg SC BID and the other half increased 
the dose to 10 µg SC BID.36–38
In two studies,37,38 a subset of patients underwent a 
standardized meal tolerance test at weeks 0, 4, and 30 
to determine the effect of EXE on postprandial glucose 
concentrations. After an overnight fast, patients took their 
morning dose of MET or MET + SU; then, patients received 
PCB or EXE injection 15 min prior to the standardized 
breakfast (55% carbohydrate, 15% protein, 30% fat based on 
body weight and activity level). Patients were excluded from 
the studies if they received thiazolidinediones, meglitinides, 
α-glucosidase inhibitors, insulins, weight-loss agents, and 
corticosteroids within 3 months of study initiation; patients 
in the SU monotherapy study could not receive MET 
and vice versa. Outcome measures included effect on 
HbA1c, tolerability, fasting and postprandial glucose levels 
(meal test), and body weight.
To determine the long-term (82 weeks) efficacy and 
tolerability of EXE, two uncontrolled, open-labeled studies 
using patients from the three 30-week studies36–38 were 
conducted. In the study by Blonde et al39 all patients that 
received EXE and completed the three 30-week initial studies 
(N = 668) were allowed to enter the open-label extension 
phase; 551 patients entered the study (ITT population) and 
314 patients were completers. The patients were allowed 
to continue SUs and MET with dose adjustments made 
as needed by provider. In the study by Ratner et al40 all 
patients who received MET + EXE and completed the 
30-week initial study (N = 183) were allowed to enter the 
open-label extension phase; 150 patients entered the study 
(ITT population) and 92 patients were completers. The 
patients were allowed to continue MET monotherapy. At the 
start of the uncontrolled phase for both studies, the patients 
received EXE 5 µg SC BID for 4 weeks followed by 10 µg 
SC BID for the duration of the study.39, 40
Patient demographics, withdrawals and results for the 
three 30-week studies36–38 and two open-label studies39,40 
are given in Tables 5 and 6. In the three 30-week stud-
ies, there was a dose-dependent, significant reduction in 
HbA1c vs PCB at 30 weeks (P  0.05); reductions began 
within the first 2 to 5 weeks of treatment.36–38 In patients 
with a baseline HbA1c  9% and on background SU mono-
therapy, the reduction in mean ± SE HbA1c was -0.65 ± 
0.12% (n = 83), -0.39 ± 0.12% (n = 79), and 0.11 ± 0.12% 
(n = 77) for those in the EXE 10 µg, EXE 5 µg, and PCB 
groups (P  0.01 and P  0.0001 vs PCB), respectively. 
In patients with baseline mean ± SE HbA1c  9%, the 
mean reduction was -1.22 ± 0.19% (n = 46), -0.58 ± 
0.24% (n = 46), vs 0.13 ± 0.17% (n = 46), (P  0.05 and 
P  0.0001), respectively. When patients with a baseline 
HbA1c  9% and received background SU + MET therapy, 
the reduction in mean HbA1c was -0.5%, -0.4%, vs 0.29%, 
(P  0.001 for both EXE groups vs PCB), respectively; 
when the baseline HbA1c  9%, the mean reduction was 
-1.35%, -0.85%, vs 0%, (P  0.001 for both EXE groups 
vs PCB), respectively (data extrapolated from figure). The 
change in HbA1c for those on MAX SUs doses and MIN 
SUs doses were -0.9 ± 0.1%, -0.7 ± 0.1%, +0.2 ± 0.1% 
and -0.6 ± 0.1%, -0.4 ± 0.1%, +0.3 ± 0.1%, respectively 
(P  0.0001 for both EXE groups vs PCB).
When patients who received EXE from the three studies 
were combined, N = 314/551 completed the open-label 
extension phase (all patients received EXE 10 µg SC 
BID).39 The mean ± SE change in HbA1c from baseline 
to week 30 during the PCB-controlled studies for these 
314 patients was -0.9 ± 0.1%; the change from baseline 
to week 82 was -1.1 ± 0.1% [95% CI –1.0 to –1.3%]. The 
change in HbA1c for those with HbA1c  9% and HbA1c  9% 
was -2.0 ± 0.2% and –0.8 ± 0.1%, respectively.39 In the 
study where patients received background MET monotherapy 
and chose to complete the open-label extension phase 
(N = 92/150), the mean ± SE change in HbA1c from baseline 
to week 30 during the PCB-controlled study for these 
92 patients was -1.0 ± 0.1%; the change from baseline Drug Design, Development and Therapy 2009:3 229
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to week 82 was -1.3 ± 0.1% [95% CI -1.5 to -1.0%, 
P  0.05].40
To determine the effect of EXE on postprandial plasma 
glucose (PPPG), the PPPG geometric mean AUC15–180 min 
values were obtained at baseline (patients received PCB 
only) and at 30 weeks (SU + MET vs SU + MET + 
EXE).38 The PPPG geometric mean AUC15–180 min for those 
in the EXE 10 µg (n = 27), EXE 5 µg (n = 27) vs PCB 
(n = 23) groups were 2033 mmol⋅min/L, 2089 mmol⋅min/L, vs 
2090 mmol⋅min/L, respectively; at week 30, the values were 
1539 mmol⋅min/L, 1584 mmol⋅min/L, vs 2087 mmol⋅min/L 
(P = 0.0004 and P = 0.0009 vs PCB), respectively.38 The 
standardized meal tolerance test was performed in a 
subset of patients in the MET study, however, the PPPG 
geometric mean AUC15–180 min were not provided.37 The 
authors stated that EXE 10 µg and 5 µg caused a significant 
reduction in PPPG vs baseline (P = 0.004 and P = 0.03), 
respectively.37
There were no significant changes to insulin concentra-
tions from baseline when patients received SU + EXE or 
MET + EXE.36–38 One study (SU + EXE) reported a signifi-
cant reduction in fasting proinsulin concentrations when 
patients received EXE 10 µg vs baseline (–16 pmol/L, 95% 
CI –26.1 to –6.0) and vs PCB (P  0.05).36 Body weight 
was reduced in all groups that received EXE 10 µg vs PCB 
(P  0.05);36–38 patients who received SU + EXE 5 µg did 
not report a significant reduction in body weight36 and those 
who received MET + EXE 10 µg reported the most weight 
loss.37 In the 314 patients who completed the 52-week 
open-label extension phase (continued background SU and 
MET plus EXE 10 µg SC BID), the mean ± SE change in 
body weight from baseline to week 30 of the PCB-controlled 
studies was -2.1 ± 0.2 kg; at week 82, the change was 
-4.4 ± 0.3 kg [95% CI –3.8 to –5.1 kg].39 When patients 
received MET + EXE, SU + EXE, or MET + SU + EXE 
during the extension phase, the mean weight reduction was 
5.3 kg, 3.9 kg, and 4.1 kg, respectively.39 In the 92 patients 
who completed the 52-week open-label extension phase 
(continued background MET plus EXE 10 µg SC BID), 
the mean ± SE change in body weight from baseline to 
week 30 of the PCB-controlled study was –3.0 ± 0.6 kg; 
at week 82, the change was -5.3 ± 0.8 kg [95% CI -7.0 
to -3.7 kg, P  0.05].40 When baseline body mass index 
(BMI)  30 kg/m2, the weight reduction was -6.9 ± 1.1 kg; 
the weight loss was less for those with a BMI  30 kg/m2 
at –2.3 ± 0.8 kg.40
In the three 30-week studies, the most commonly 
reported adverse events (AEs) in the EXE 10 µg (N = 483), 
EXE 5 µg (N = 480), and PCB (N = 483) groups included 
hypoglycemia (N = 119 or 25%, N = 70 or 15%, and N = 41 
or 9%) and nausea (N = 234 or 48%, N = 185 or 39%, and 
N = 86 or 18%), respectively.36–38 Patients reported that 
the hypoglycemia and nausea were of mild-to-moderate 
severity and peaked within the first 2 months of treatment. 
More patients in the SU-only study and SU + MET study 
receiving EXE reported hypoglycemia vs those receiving 
SU alone, SU + MET alone, MET alone, or MET + EXE 
therapies.36–38 In the SU + MET study,38 the incidence of 
hypoglycemia for those on MAX SUs and MIN SUs dosages 
were and randomized to EXE 10 µg, 5 µg, and PCB similar 
at 35%, 22%,15%, and 21%, 16%, 10%, respectively.
Post-hoc analyses revealed no correlations between 
weight loss and nausea in the three studies.36–38 In the 
background SUs monotherapy study,36 the mean ± SD weight 
loss for those in the EXE 10 µg, EXE 5 µg, and PCB groups 
but never reported nausea were -1.4 ± 3.6 kg (61 patients), 
-0.6 ± 3.0 kg (75 patients), and -0.7 ± 3.1 kg (110 patients); 
respectively; in those who had 1 episode of nausea, the 
weight loss was -1.7 ± 3.2 kg (65 patients), -1.3 ± 2.9 kg 
(48 patients), and 0.6 ± 4.7 kg (9 patients), respectively.36 
In the background SU + MET study, the weight loss for those 
who never experienced nausea was -1.1 ± 0.3 kg (10-µg 
group) and -1.7 ± 0.2 kg (5-µg group). Both open-label 
extension studies reported that there were no correlations 
with weight loss and nausea (r = -0.11 for the SU + MET 
extension study)39 and (r = -0.071 for the MET extension 
study).40
An interim analysis was performed to evaluate the 
association among observed changes in glycemic control, 
weight reduction, and liver injury biomarkers in patients 
from the above-mentioned 3 studies who completed 2 years 
of EXE therapy.41 The 2-year completer cohort (N = 283, 
demographics in Table 5) was defined as all subjects who had 
the opportunity to achieve 2 years of EXE exposure, regardless 
of their treatment arm in the 30-week placebo-controlled 
studies. At 104 weeks, there was a statistically significant 
reduction in HbA1c, weight, and fasting plasma glucose 
compared with baseline (P  0.001 for all comparisons) 
(Table 6). In 213 patients with a mean baseline HbA1c 
7.8%, the mean ± SE change was -0.9% ± 0.1%; in those 
with a mean HbA1c 9.7% (n = 70), the mean ± SE change 
was -2.0% ± 0.2%. The mean ± SE change in HbA1c stratified 
by BMI was similar for patients with a baseline BMI  30, 
30 but 40, and 40 at -1.2% ± 0.1%, -1.1% ± 0.1%, 
and -1.2% ± 0.2%, respectively. HOMA-B data were collected 
in 112 patients and significantly increased from baseline Drug Design, Development and Therapy 2009:3 232
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(mean ± SE 50%, P  0.01; numerical value extrapolated 
from figure) with a smaller improvement in HOMA-S 
(8.3% change in median HOMA-S; P  0.01 vs baseline). 
There was a reduction in mean ALT (–5.3 IU/L; 95% CI -7.1 
to -3.5, P  0.05) and AST (-2.0 IU/L; 95% CI -3.3 
to -0.8, P  0.05) values at week 104. Those with elevated 
ALT and AST at baseline showed a reduction at week 104: 
-11 IU/L; 95% CI -14 to -8, P  0.001 and -5 IU/L, 
95% CI -7 to -3, P  0.001, respectively. Baseline mean 
SBP and DBP were 130.2 ± 0.8 mmHg and 78.8 ± 0.5 mmHg; 
at week 104, a reduction in SBP (-2.6 ± 0.9 mmHg 
(95% CI -4.3 to -0.9, P = 0.003) and DBP (-1.9 ± 0.5 mmHg 
(95% CI -3.0 to -0.9, P  0.001) was observed. Forty-
five of 238 patients withdrew due to adverse events; mild 
to moderate nausea was the most frequently reported AE, 
independent of age, with 3% withdrawing over the 2 years 
because of nausea (Table 6).
Elkind-Hirsch et al42 conducted an open-label, prospective, 
randomized, outpatient clinical study over 24 weeks to 
determine the change in menstrual frequency in patients 
with PCOS (polycystic ovary syndrome). Patients were 
randomized to MET 1000 mg BID (N = 20, mean ± SEM 
age 27.7 ± 1.3 years), EXE 10 µg BID (N = 20, mean ± 
SEM age 28.2 ± 1.1 years), or MET + EXE (N = 20, mean ± 
SEM age 32.1 ± 0.7 years) and underwent clinical, metabolic, 
and laboratory evaluations before, after 12 weeks and after 
24 weeks of treatment. Forty-two patients completed the study 
(14 per group). At baseline, the mean ± SEM frequency of 
menstrual cycles/year (calculated using the ratio of expected 
menses to observation week, ie, 12 cycles/52 weeks) were 
0.21 ± 0.04, 0.22 ± 0.04, and 0.29 ± 0.037, respectively; at 
24 weeks, the frequency of menstrual cycles/year were 0.49 ± 
0.08, 0.57 ± 0.08, and 0.83 ± 0.082, respectively (P = 0.0001 
overall effect after all treatments; P = 0.018 MET + EXE vs 
MET; P = 0.091 MET + EXE vs EXE). For patients random-
ized to MET, EXE 10 µg or MET + EXE the ovulation rates 
were 29% (4/14 patients), 50% (7/14), and 86% (12/14), 
respectively. At baseline, the mean ± weight was 113.4 ± 7 kg, 
110.5 ± 6 kg, and 112 ± 8 kg, respectively; at 24 weeks, the 
mean ± SE weight loss was 1.6 ± 0.2 kg, 3.2 ± 0.1 kg, and 
6 ± 0.5 kg, respectively (P = 0.001 for overall effect after 
all treatments; P = 0.019 for both groups with EXE vs MET 
monotherapy). Total testosterone and free androgen index 
were reduced in all groups (P  0.05 overall effect after 
all treatments) but SHBG (sex hormone binding globulin) 
and DHEAS (dehydroepiandrosterone sulfate) remained 
unchanged. Seven of 11 women with glucose intolerance at 
baseline had normal glucose at 24 weeks (3/5 on MET, 1/3 
on EXE, and 3/3 on MET + EXE). HOMA-IR and insulin 
sensitivity as determined by a 75-g oral glucose tolerance 
test, improved in all groups (P  0.05 overall effect after all 
treatments); insulin sensitivity improved most in those who 
received MET + EXE vs EXE (P = 0.022) but not vs MET. 
The most frequent AEs for those in MET, EXE, and MET + 
EXE groups included nausea (4/20, 3/20, and 9/20) and 
diarrhea (6/20, 0/20, and 2/20). Pregnancy occurred in 2/20, 
1/20, and 1/20 patients, respectively.
Efficacy with rosiglitazone 
and pioglitazone
Pinelli et al43 performed a meta-analysis to compare the 
effects of adding EXE vs TZDs on glycemic control and 
tolerability. The studies used in this analysis compared 
either TZDs or EXE with comparable controls, but not in 
combination with each other so that the difference due to 
TZDs or to EXE relative to the control could be estimated. 
The magnitudes of the changes were then compared between 
TZDs and EXE to evaluate the difference between the two 
drug classes. Twenty-two publications were used in the 
analysis: 8 TZD and 3 EXE studies evaluated the respec-
tive agents in combination with MET, SU, SU + MET in a 
double-blind, placebo-controlled fashion; 9 TZD and 2 EXE 
studies compared the efficacy of the respective agents with 
other glucose-lowering agents and open-label SC insulin 
(glargine and biphasic aspart).43
The reduction in HbA1c (weighted mean differences) 
when patients received TZD-based regimens vs EXE-based 
regimens was -0.80% [95% CI -1.10 to -0.50] vs -0.60% 
[95% CI -1.04 to -0.16], respectively. In studies where 
the comparator was a PCB, the reduction (weighted mean 
differences) in HbA1c for those who received TZDs vs 
PCB was -1.14% [95% CI -1.30 to -0.98] vs -0.97% 
[95% CI -1.11 to -0.83]. No difference in reduction of 
HbA1c was seen with use of EXE vs insulin (-0.08 [95% CI 
-0.23 to 0.07]), but a significant reduction in HbA1c seen in 
favor of TZD vs active controls (-0.38 [95% CI -0.75 to 
-0.01]). The odds ratio (OR) of reaching HbA1c  7% was 
2.27 [95% CI 1.22 to 4.24] vs 2.90 [95% CI 1.28 to 6.55], 
for those who received TZD-based regimens vs EXE-based 
regimens, respectively.43 Compared with PCB, treatment 
with TZD or EXE increased OR of reaching HbA1c  7% 
(OR 3.72 [95% CI 2.80 to 4.93]) and (OR 5.72 [95% CI 3.87 
to 8.46]), respectively; however, this effect on OR was not 
seen when compared with active treatment: TZD vs active 
controls (OR 1.40 [95% CI 0.71 to 2.75]) and EXE vs insulin 
(OR 1.15 [95% CI 0.73 to 1.80]), respectively.43Drug Design, Development and Therapy 2009:3 233
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The pooled OR of developing nonsevere hypoglycemia 
after exposure to TZD-based regimens was not significantly 
different from other treatment arms (OR 1.59 [95% CI 0.76 
to 3.32]). In 3 EXE, placebo-controlled studies,36-38 the risk of 
hypoglycemia did not achieve significance (OR 3.53 [95% CI 
0.92 to 13.61]). The change in body weight from baseline for 
those who received TZDs was nonsignificant vs comparator 
groups (weighted mean difference 1.51 kg [95% CI -0.12 to 
3.15]). Mean change in body weight was reduced significantly 
in patients who received EXE-based regimens (weighted 
mean difference -2.74 kg [95% CI -4.85 to -0.64]); the 
reduction in body weight for those who received EXE in 
the three placebo-controlled studies36-38 was -1.29 kg [95% 
CI -2.22 to -0.36] and -4.79 kg [95% CI -6.06 to -3.52] 
for those who received insulin as the active comparator. The 
pooled OR for the reporting of GI adverse events (nausea, 
vomiting, diarrhea) by those receiving EXE-based regimens 
was 9.02 [95% CI 3.66 to 22.23], 4.56 [95% CI3.13 to 6.65], 
and 2.96 [95% CI 2.05 to 4.26], respectively.
Zinman et al44 conducted a randomized, double-blind, 
16-week study to determine the effects on glycemic control 
by the addition of EXE to TZDs (with or without MET) vs 
TZDs + PCB. After a 2-week PCB lead-in period where all 
patients injected PCB SC BID 15 min before the morning 
and evening meals, patients randomized to EXE began active 
treatment (5 µg BID for 4 weeks followed by 10 µg BID 
for 12 weeks). All patients received a TZD (rosiglitazone, 
4 mg/day, or pioglitazone, 30 mg/day). Patient demo-
graphics, withdrawals, glycemic measurements, and 
adverse events are found on Table 7. Compared with PCB, 
patients receiving EXE + TZD reported a statistically sig-
nificant reduction in HbA1c, fasting serum glucose, daily 
mean postprandial glucose excursions, and body weight, 
P  0.001 for all comparisons. The change in HbA1c did 
not vary based on existing oral antihyperglycemic treatment 
at baseline (P = 0.87 for interaction). Postprandial glucose 
excursions were significantly reduced for patients receiving 
EXE (mean ± SE AM change -1.73 ± 0.27 mmol/L and PM 
change -1.68 ± 0.30 mmol/L, P  0.001 vs PCB for both 
time points). β-cell function improved by 19% for those who 
received EXE vs a reduction of 6% for those who received 
PCB (P = 0.005); insulin sensitivity increased by 23% in the 
EXE group vs 10% in the PCB group at week 16 (P = 0.20). 
There was a significant reduction in body weight seen in 
patients receiving EXE starting from week 4 (P  0.01 vs 
PCB) to week 16 (P  0.001 vs PCB). The reductions in 
weight occurred to a similar extent in those with and with-
out nausea: mean ± SE change -1.95 ± 0.43 kg and -1.25 
± 0.35 kg, respectively. Adverse events occurred in 76% 
vs 65.2% of patients in the EXE vs PCB group (difference 
EXE – PCB = 10.9 [95% CI -1.7 to 23.4]) (Table 7). 
Nausea and vomiting were common AEs reported by those 
receiving EXE vs PCB with 11 patients discontinuing the 
study due to nausea and 2 discontinuations due to vomiting; 
however, the investigators felt that the nausea experienced 
by patients who received EXE was mostly mild (n = 21 
[44%]) or moderate (n = 19 [40%]) and intermittent.
In summary, the above meta-analysis showed that the 
use of TZDs may provide a slight advantage over EXE in 
improving HbA1c along with increased weight gain; those 
who received EXE lost weight, but experienced more GI 
adverse effects. The authors reported that the studies (TZDs 
vs EXE studies) used to determine the effect of the agents 
on HbA1c were different and 2 points should be taken into 
consideration: 1) more patients in TZDs studies had base-
line HbA1c  9% vs 0% of patients in EXE studies; and, 
2) studies with EXE reported using maximally effective 
doses of SU/MET and EXE vs only half of the studies of 
TZDs reported use of maximally effective background 
therapy and TZD dosages.43
One study compared the effect of glycemic control and 
tolerability of adding EXE 10 µg BID to TZD ± MET.44 Over 
16 weeks, patients randomized to EXE reported a reduction 
in HbA1c of 0.89% vs TZD ± MET, fasting serum glucose of 
–1.59 mmol/L, postprandial glucose of 1.58 mmol/L, and 
body weight of –1.75 kg (P  0.001 for all comparisons vs 
PCB). Nausea, vomiting, nasopharyngitis and hypoglycemia 
were the most commonly reported AEs for those randomized 
to EXE vs TZDs (93/121 or 77% vs 35/112 or 31%).
Efficacy with insulins
Heine et al45 conducted a multicenter, randomized, open-label, 
phase 3 clinical study to compare the effects of EXE vs insulin 
glargine (GLA) over 26 weeks in patients with type 2 DM 
receiving SU + MET. Patients randomized to EXE received 
5 µg SC BID for 4 weeks with an increase to 10 µg SC BID 
for 22 weeks. Patients randomized to GLA initially received 
10 units/day and self-titrated by 2 units every 3 days to achieve 
a fasting blood glucose target level 5.6 mmol/L. MET and 
SU doses were fixed at prestudy levels unless patients experi-
enced hypoglycemia; if this AE occurred, a 50% reduction in 
SU dose was recommended. Severity of AE (mild, moderate, 
or severe) and its attribution to therapy (yes, no) were assessed 
by the investigator. Patients from 21 sites participated in a meal 
study where glucose levels were determined before a meal 
(fasting) and 1 to 4 hours after the meal. The noninferiority Drug Design, Development and Therapy 2009:3 234
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margin for the difference between treatments (EXE minus 
GLA) on HbA1c was defined as 0.4%.
Patient demographics for those in the EXE group 
(N = 282) and GLA group (N = 267) were as follows: 55% 
males; 79.8% Caucasians, 15.6% Hispanics; mean ± SD age 
59.8 ± 8.8 years; mean ± SD duration of DM 9.9 ± 6.0 years 
and 56.6% males; 80.5% Caucasians, 15.0% Hispanics; 
58.0 ± 9.5 years of age; duration of DM 9.2 ± 5.7 years. 
Results of glycemic control and body weight are found 
on Table 8. At 26 weeks, patients in both groups achieved 
a similar reduction in HbA1c with similar percentages 
reaching HbA1c  7% (46% vs 48%), respectively. The 
average GLA at week 26 was 25 units/day (N = 244), and 
21.6% of those in the GLA group vs 8.6% of those in the 
EXE group achieved a FPG  5.6 mmol/dL, P  0.001 
vs EXE. Patients in the EXE group began to lose weight 
within 2 weeks of therapy vs weight gain by those in the 
GLA group (P  0.0001); weight loss by those in the EXE 
group who did not report nausea (n = 120) was -1.9 kg 
[CI -2.5 to -1.4 kg] and was similar for those who did 
Table 7 Patient demographics and mean changes from baseline in glycemic control and reported adverse events after the addition of 
exenatide to TZD ± metformin therapy after 16 weeks44
  Exenatide (N = 121) Placebo (N = 112)
Male, n (%) 65 (53.7) 64 (57.1)
Race, n (%) 
  white 
  Other
 
103 (85.1) 
18 (14.9)
 
92 (82.1) 
20 (17.9)
Mean age ± SD (y) 55.6 ± 10.8 56.6 ± 10.2
Mean duration of DM ± SD (y) 7.3 ± 4.9 8.2 ± 5.8
TZD stratum, n (%) 
  TZD alone 
  TZD + MeT
 
28 (23.1) 
93 (76.9)
 
22 (19.6) 
90 (80.4)
Mean MeT dose ± SD (mg) 1804 ± 459 1810 ± 420
withdrawals, n 
  Adverse events 
  Loss of glucose control 
  Other
35  
19  
2  
14
16  
2  
1  
14
Exenatide (N = 121) Placebo (N = 112) Difference [95% CI]***
BL 16 wk BL 16 wk
HbA1c (%) 
  TZD + eXe (n = 27) vs PCB (n = 19) 
  TZD + MeT + eXe (n = 90) vs PCB (n = 86)
7.9 ± 0.9* 
7.93 ± 0.87* 
7.88 ± 0.92*
-0.89 ± 0.09** 
7.15 ± 1.05* 
7.10 ± 0.92*
7.9 ± 0.8* 
7.83 ± 0.89* 
7.93 ± 0.79*
0.09 ± 0.10** 
7.90 ± 0.93* 
8.02 ± 1.13*
-0.98 [-1.21 to -0.74]a
Fasting serum glucose (mmol/L) 9.1 ± 2.6* -1.59 ± 0.22** 8.8 ± 1.9* 0.10 ± 0.21** -1.69 [-2.22 to -1.17]a
Daily mean SMBG – postprandial (mmol/L) 1.74 -1.58 1.99 -0.31 -1.27 [-1.64 to -0.91]a
HOMA of β-cell function (%) 37.85 ± 2.46** 1.19c 35.91 ± 2.50** 0.94c 1.27 [1.08 to 1.51]b
HOMA of insulin sensitivity (%) 71.55 ± 4.22** 1.23c 78.58 ± 5.56** 1.10c 1.11 [0.94 to 1.31]
Body weight (kg) 97.53 ± 1.73** -1.75 ± 0.25** 96.75 ± 1.81** -0.24 ± 0.26** -1.51 [-2.15 to -0.88]a
Adverse events, n (%) 
  Nausea 
  Nasopharyngitis 
    vomiting 
  Hypoglycemia 
  edema 
  Dyspepsia 
  Diarrhea
 
48 (39.7) 
16 (13.2) 
16 (13.2) 
13 (10.7) 
7 (5.8) 
9 (7.4) 
7 (5.8)
 
17 (15.2) 
9 (8.0) 
1 (0.9) 
8 (7.1) 
9 (8.0) 
1 (0.9) 
3 (2.7)
 
24.5 [12.7 to 36.3] 
5.2 [-3.5 to 13.9] 
12.3 [5.2 to 19.5] 
3.6 [-4.6 to 11.8] 
-2.3 [-9.6 to 5.1] 
6.5 [0.7 to 12.4] 
3.1 [-2.9 to 9.1]
Notes: *Mean ± SD; **mean ± Se; ***difference (reported in percentage points) is calculated as eXe (exenatide) minus PCB; aP  0.001 vs PCB; bP = 0.005 vs PCB; cChanges 
in HOMA of β-cell function and HOMA of insulin sensitivity were performed on log-transformed data where the analysis variable was a change [log(final)-log (baseline)] and 
where back-transformations were expressed as ratios.
Abbreviations: BL, baseline; HbA1c hemoglobin A1c; SMBG, self-monitoring of blood glucose; HOMA, homeostasis model assessment; MeT, metformin; TZD, thiazolidinedione; 
PCB, placebo.Drug Design, Development and Therapy 2009:3 235
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report nausea (data not provided). Patients receiving GLA 
had lower glucose levels at fasting (P  0.001), before 
meals (prelunch, P = 0.023; predinner, P = 0.006), and at 
03:00 h (P  0.001), but they had higher glucose levels 
after morning (P  0.001) and evening meals (P  0.001) 
vs EXE. Those receiving EXE reported lower glucose levels 
after the morning (P  0.001) and evening (P  0.001) 
meals vs GLA. The change in total glucose 4-hour AUC 
(from baseline) after the test meal study for those in the 
EXE (n = 41) vs GLA (n = 37) groups was similar between 
the two groups: -12.9 mmol⋅h/L vs -13.3 mmol⋅h/L 
[CI -4.0 to 4.7 mmol⋅h/L].45
A total of 54 vs 25 patients in the EXE vs GLA 
groups withdrew from the study. Reasons included 
AEs (27 vs 2) and loss of glucose control (4 vs 0); 
23 patients from both groups withdrew due to protocol 
violations or were lost to follow-up. The most common 
AEs by those in the EXE vs GLA group included nausea 
(57.1% vs 8.6%, P  0.001), vomiting (17.4% vs 3.7%, 
P  0.001), diarrhea (8.5% vs 3.0%, P = 0.006), upper 
abdominal pain (4.3% vs 0.7%, P = 0.012), constipation 
(3.5% vs 0.4%, P = 0.011), dyspepsia (3.5% vs 0.4%, 
P = 0.011), anorexia (3.5% vs 0%, P = 0.002) and decreased 
appetite (3.2% vs 0.4%, P = 0.021); indeed, 55% in this 
Table 8 Mean changes from baseline in HbA1c, fasting glucose, and body weight in patients (intention-to-treat) receiving exenatide vs 
insulins45,47,48
  HbA1c (%)
Heine et al45 BL wk 26 Difference between the groups 
[95% Ci]a
eXe (N = 275) 8.2 ± 1.0 –1.11b,c 0.017 
GLA (N = 260) 8.3 ± 1.0 –1.11b,c [–0.123 to 0.157]
Nauck et al47 BL wk 52 –0.15 
eXe (N = 253) 8.6 ± 1.0 –1.04 ± 0.07b,d,e [–0.32 to 0.01], (P = 0.067)
BiASP (N = 248) 8.6 ± 1.1 –0.89 ± 0.06b,d,e
Fasting glucose (mmol/L)
Heine et al45 BL wk 26 Difference between the groups 
[95% Ci]a
eXe (N = 275) 10.1 ± 2.6 –1.4 –1.5 
GLA (N = 260) 10.4 ± 2.9 –2.9f [–1.1 to –1.9]
Nauck et al47 BL wk 52 –0.1 
eXe (N = 253) 11.0 ± 2.7 1.8 ± 0.2d,e [–0.6 to 0.4], (P = 0.689)
BiASP (N = 248) 11.3 ± 2.8 –1.7 ± 0.2d,e
Body weight (kg)
Heine et al45 BL wk 26 Difference between the groups 
[95% Ci]a
eXe (N = 275) 87.5 ± 16.9 –2.3f –4.1 
GLA (N = 260) 88.3 ± 17.9 1.8 [–4.6 to –3.5]
Nauck et al47 BL wk 52 –5.4
eXe (N = 253) 85.5 ± 15.7 –2.5 ± 0.2d,e [–5.9 to –5.0], (P  0.001)
BiASP (N = 248) 83.4 ± 15.6 +2.9 ± 0.2d,e
Exenatide (N = 532) Insulins (N = 515)
Glass et al48,h BL, n (%) endpoint, n (%) BL, n (%) endpoint, n (%)
BMi  25 20 (3.8) 51 (9.6)i,j 27 (5.2) 20 (3.9)
BMi 25–29 220 (41.4) 222 (41.7) 227 (44.1)i 213 (41.4)
BMi  30 292 (54.9) 259 (48.7)i,j 261 (50.7)i 282 (54.8)i
Notes: values presented as mean ± SD, unless otherwise noted aexenatide minus insulin; bPercentage points; cChange from baseline (least-squares means are obtained from 
a statistical model that includes baseline as a covariate); dMean (SeM) (least-squares mean changes were obtained from a mixed model repeated-measures anaysis of covari-
ance); eP  0.001 for BL to week 52 within-group change; fP  0.0001 in favor of eXe; gP  0.001 in favor of GLA; hPooled post-hoc analysis of Heine et al and Nauck et al; 
iP  0.0001 vs BL; jP  0.0001 vs insulin.
Abbreviations: BiASP, biphasic aspart (30% rapid-acting aspart); BMi, body mass index, kg/m2; eXe, exenatide; GLA, glargine; HbA1c, hemoglobin A1c.Drug Design, Development and Therapy 2009:3 236
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group reported 1 episode of nausea during the first 
2 months and 13% reported nausea during the last 2 months 
of the study (32.6%, 19.9%, and 4.6% with mild, moder-
ate, or severe intensity); 18 patients (vs 1 in GLA group) 
withdrew due to nausea. The overall rate of hypoglycemia 
was similar across treatment groups (7.3 events/patient-
year vs 6.3 events/patient-year in the EXE vs GLA group 
[difference 1.1 CI -1.3 to 3.4 events/patient-year]). The 
rate of nocturnal hypoglycemia was 0.9 events/patient-year 
vs 2.4 events/patient-year [difference -1.6 CI -2.3 to -0.9 
events/patient-year], respectively. The rate of daytime 
hypoglycemia was 6.6 events/patient-year vs 3.9 events/
patient-year [difference 2.7 CI 0.4 to 4.9 events/patient-
year], respectively. The percent of patients who achieved 
a HbA1c  7% and reported a symptomatic hypoglycemic 
episode was 61% vs 68%, respectively; 21% vs 43% 
reported an episode of nocturnal hypoglycemia.45
A secondary analysis of the above-mentioned study45 was 
conducted by Boye et al46 determined the effect of treatment 
on change in patient-reported health outcomes measures. 
Five health outcomes instruments were completed at baseline 
(week 0) and endpoint (week 26). These were: 1) Diabetes 
Symptom Checklist-revised (DSC-R) which measured the 
frequency and perceived discomfort of physical and psy-
chological symptoms associated with type 2 diabetes and its 
potential complications; 2) Diabetes Treatment Flexibility 
Scale (TFS) which evaluated how much choice patients have 
in their decisions concerning meals and physical, social, 
and other daily activities during the past month; 3) Diabetes 
Treatment Satisfaction questionnaire (DTSQ) which mea-
sured diabetes treatment regimens among patients with 
type 1 and type 2 DM; 4) EuroQol EQ-5D which provided 
an estimate of overall health status; and 5) Vitality scale of 
the SF-36 which assessed energy level and fatigue. When 
compared with baseline scores, both agents caused a sig-
nificant improvement in DSC-R overall score, DTS score, 
SF-36 Vitality subscale score, DSC-R Psychology Fatigue 
and Cognitive scores, DSC-R Ophthalmology score, DSC-R 
Hypoglycemia score, DSC-R Hyperglycemia score, DTSQ 
Frequency High Blood Sugar and Low Blood Sugar scores 
(P  0.04 for all vs baseline). However, there was not a 
statistically significant difference between the two groups in 
change in health outcomes.
Nauck et al47 conducted a multicenter, randomized, 
open-label, non-inferiority study to compare the effects of 
EXE vs biphasic aspart 30/70 (30% rapid-acting aspart, 
BIASP) over 52 weeks in patients with type 2 DM receiving 
SU + MET. Patients randomized to EXE received 5 µg SC 
BID for 4 weeks with an increase to 10 µg SC BID for the 
duration of the study; if frequent nausea developed (daily 
episodes .1 week duration), patients had the option to 
decrease their dose to 5 µg BID. Patients randomized to 
insulin BIASP initially received an amount determined 
by their physicians; a forced titration schedule was not 
used in the study, and investigators were instructed to 
adjust insulin doses to achieve an optimal balance between 
glucose control and risk of hypoglycemia. MET and SU 
doses were maintained at optimally effective prestudy 
levels unless patients experienced hypoglycemia; if this AE 
occurred, a 50% reduction in SU dose was recommended. 
Severity of AE (mild, moderate, or severe) and its attribution 
to therapy (yes, no) were assessed by the investigator. 
The non-inferiority margin for the difference in HbA1c 
change between treatments was predefined as 0.4%, with 
non-inferiority demonstrated by excluding the 0.4% nonin-
feriority margin with the upper limit of a two-sided 95% CI 
for the mean difference between treatment.47
Patient demographics for those in the EXE group 
(N = 253) and BIASP group (N = 248) were as follows: 
53% males; mean ± SD age 59.0 ± 9.0 years; mean ± SD 
duration of DM 9.8 ± 6.3 years and 49% males; 58.0 ± 9.0 
years of age; duration of DM 10.0 ± 6.2 years. Results of 
glycemic control and body weight are found on Table 8. At 52 
weeks, 80% of patients in the EXE group (195/245) were 
using 10 µg BID and the mean dose of BIASP increased 
from 15.7 ± 9.5 units/day at week 2 to 24.4 ± 15.6 units/day. 
More patients in the EXE group had SU dose reduced during 
the study (33% vs 5%), respectively. Based on the change 
of HbA1c, treatment with EXE was noninferior to treatment 
with BIASP. More patients in the EXE group achieved 
HbA1c  7% (32% vs 24%, P = 0.038). Based on SMBG 
(premeals, 2 hours postmeals, and 03:00 h), both groups 
reduced glucose levels at all time points (all within group 
values, P  0.001); BIASP group had significantly lower 
mean glucose values prebreakfast (P = 0.037), prelunch 
(P = 0.004), and 03:00 h (P = 0.002); patients randomized 
to EXE reported lower 2-hour postbreakfast (P  0.001) and 
postsupper (P  0.001) mean glucose values. Patients in the 
EXE group began to lose weight at week 2 and progressed 
to a difference of –5.5 ± 0.2 kg (least-squares mean ± SEM, 
95% CI –5.9 to –5.0 kg, P  0.001) vs BIASP at week 52. 
The weight loss for those who were on EXE and had 1 
episode of nausea or vomiting vs those without nausea/vom-
iting was similar at –2.7 ± 3.2 kg, n = 94 and –2.1 ± 3.4 kg, 
n = 157, respectively. A statistically significant mean 
reduction in both systolic (–5 ± 15 mmHg, P  0.001 vs BL) Drug Design, Development and Therapy 2009:3 237
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and diastolic (–2 ± 10 mmHg, P = 0.03 vs BL) blood pressure 
was reported for those receiving EXE but not BIASP.47
Of 501 randomized patients, 199 patients in the EXE 
and 223 patients in the BIASP groups completed the study; 
20/54 patients in the EXE withdrew due to AEs vs 0/25 
in the BIASP group. The most commonly reported AEs 
for those in the EXE (ITT sample N = 253) vs BIASP 
(ITT sample N = 248) groups, included nausea (33.2% vs 
0.4%), vomiting (15.0% vs 3.2%), nasopharyngitis (11.1% 
vs 9.7%), and diarrhea (9.5% vs 2.0%). In total, 5.1% of 
patients withdrew from the EXE group due to GI AEs. The 
overall hypoglycemia rates (least-square means ± SEM) 
at endpoint for those in the EXE vs BIASP groups were 
4.7 ± 0.7 events/patient-year vs 5.6 ± 0.7 events/patient-
year, respectively; the rates of daytime and nocturnal 
hypoglycemia was similar between the 2 groups and the 
overall hypoglycemia rates decreased when SU doses were 
lowered for those receiving EXE (mean ± SD: before SU 
reduction, 26.9 ± 43.3 events/patient-year; after SU reduc-
tion, 6.1 ± 8.3 events/patient-year); data about SU doses for 
BIASP group not provided.47
Glass et al48 pooled data from the above two studies,45,47 
to analyze the effect of EXE vs insulins (GLA or BIASP) on 
weight after 6 months of treatment. Patient demographics for 
those receiving EXE were as follows: N = 532, mean ± SD 
age 59.4 ± 8.8 years, 54.3% males, 87% Caucasians and 
8.3% Hispanics, 9.9 ± 6.1 years with DM; for those in 
the INS group, N = 515, 58.2 ± 9.3 years, 53% males, 
86.6% Caucasians and 7.8% Hispanics, with 9.6 ± 6.0 
years with DM. Patient classification based on weight and 
study agent can be found on Table 8. At 6 months, both 
groups reported a significant reduction in HbA1c (EXE: 
-1.06 ± 0.05, P  0.0001 vs BL; INS: -1.05 ± 0.04, 
P  0.0001 vs BL). Those treated with EXE had an average 
weight loss of 2.3 kg and those treated with INS gained an 
average of 1.8 kg. At endpoint, a higher number of patients 
in the EXE group reported a BMI  25 kg/m2 (P  0.0001 
vs BL and P  0.0001 vs INS) and a smaller number of 
patients reported a BMI  30 kg/m2 (P  0.0001 vs BL 
and P  0.0001 vs INS); more patients in the INS group 
reported a BMI  30 kg/m2 vs BL (P  0.0001).48
Tolerability
None of the studies reviewed reported toxicity to any major 
organs or clinically significant changes in laboratory test 
results, physical findings, diagnostic testing or vital signs. 
Nausea, hypoglycemia, vomiting and nasopharyngitis44 were 
the most commonly reported adverse drug events.36–47
Nausea was most frequently (.20%) reported in 
patients receiving the highest dose of EXE (10 µg SC 
BID vs 5 µg SC BID).36–47 Hypoglycemia was mostly 
reported in patients receiving the combination treatment of 
sulfonylurea + metformin + EXE (.30%)38 .sulfonylurea 
alone (.15)36 .metformin alone (5%).37 To minimize 
these common GI and hypoglycemia adverse events, EXE 
dose escalation is recommended.20,49
The FDA issued an update on November 18, 2008 
about new cases of hemorrhagic/necrotizing pancreatitis 
(HNP) in patients taking EXE.50 Between June 2005 and 
July 2007, the cumulative spontaneous reporting rate of 
HNP is 0.20 events per 1000 patient-years of exposure. 
Patients at a high risk for experiencing HNP while 
receiving EXE include patients with a history of gall 
stones, hypertriglyceridemia and excess alcohol intake. 
Symptoms of HNP are persistent severe abdominal pain 
with or without excessive nausea and vomiting while 
receiving EXE therapy. The FDA has advised healthcare 
professionals to instruct their patients to seek immediate 
medical attention if these symptoms commence suddenly 
while receiving EXE.50
Dosing and administration
In the US, EXE is supplied as a sterile solution for 
subcutaneous injection in 1.2 mL (5 µg/0.2 mL, 60 doses) 
and 2.4 mL (10 µg/0.4 mL, 60 doses) prefilled pens.20 Each 
milliliter of EXE contains 250 µg of synthetic EXE, mannitol 
as atonicily-adjusting agent, 2.2 metacresol as an antimi-
crobial preservative, and glacial acetic acid/sodium acetate 
trihydrate as a buffering solution (pH = 4.5).20 EXE should 
be administered as a SC injection in the thigh, abdomen 
or upper arm within the 60-min period before the morning 
and evening meals. EXE should not be administered after 
meals. The recommended starting dose is 5 µg SC BID. EXE 
dose can be titrated up to 10 µg SC BID after 1 month of 
therapy with the 5 µg SC BID regimen. EXE prefilled pens 
should be kept refrigerated and not frozen until first use. 
Once used, the prefilled pens can be kept in the refrigerator 
or at room temperature not exceeding 77° F (25 °C) for up 
to 30 days.20
The use of EXE is contraindicated in patient with known 
hypersensitivity to the drug or any of its components. EXE 
is listed as a pregnancy category C drug and should be used 
during pregnancy only if the potential benefits outweigh the 
risk to the fetus. It is unknown whether EXE is excreted in 
human milk and therefore, caution should be exercised with 
nursing women.20Drug Design, Development and Therapy 2009:3 238
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Pharmacoeconomic considerations
The average wholesale price of the 1.2 mL (5 µg/0.2 mL) 
and the 2.4 mL (10 µg/0.4 mL) prefilled pens are US$240.84 
and US$282.63, respectively.51 Both prefilled pens contain 
enough medication for a month.
The literature search identified one study that evaluated 
the potential cost effectiveness of treating patients with 
EXE as an adjunctive therapy in type 2 DM. Minshall 
et al52 conducted a long-term cost effectiveness study using 
30-year base case assumptions and data from 82 weeks 
(from 30-week clinical trials + 52 weeks of subsequent 
open-label extensions) to estimate the effects of 30 years 
of EXE adjunctive treatment in patients with type 2 DM. 
The analysis found that using EXE for 30 years compared 
with no additional treatment beyond sulfonylurea and/or 
metformin yields an incremental cost-effectiveness ratio 
of US$35,571.52
Discussion
It appears that when patients received EXE 10 µg SC BID 
in the three, 30-week, placebo-controlled studies with back-
ground SUs, MET, or SU + MET, there was a significant 
reduction in HbA1c (0.77% to 0.86%), fasting plasma glucose 
(0.6 mmol/L), and body weight(1.6 to 2.8 kg) (P  0.05 
vs PCB). The beneficial effect of EXE was maintained in 
patients who completed the two open-label phase trials with 
an additional 52 weeks of therapy. Gastrointestinal events 
were seen more commonly in those randomized to EXE with 
nausea occurring in 43.5% of patients (419/963 ITT patients 
receiving EXE) vs 26% of patients receiving PCB (126/483 
ITT patients). More patients receiving EXE 10 µg or when 
patients received concomitant MET therapy complained of 
nausea vs the 5-µg dose or SU monotherapy. Most patients 
reported nausea and other GI AEs to be mild-to-moderate in 
severity and 2% to 4% of patients receiving EXE withdrew 
from the study due to nausea. Hypoglycemia occurred in 
20% (189/963) vs 9% (42/483) of patients receiving EXE vs 
PCB; this AE occurred more commonly in those receiving 
SUs + MET . SUs only .MET only.
The use of TZDs may provide a slight advantage over 
EXE in improving HbA1c along with increased weight gain; 
those who received EXE lost weight, but experienced more 
GI adverse effects. The authors reported that the studies (TZDs 
vs EXE studies) used to determine the effect of the agents on 
HbA1c were different and should be taken into consideration. 
When comparing EXE treatment with insulin treatment, 
patients receiving EXE lost significant body weight while 
patients receiving insulin gained weight. Further, patients 
receiving insulin had lower fasting, prelunch, and predinner 
glucose levels while patients in the EXE groups exhibited 
lower postprandial glucose levels.
Future directions
Long-term, head-to-head studies assessing the effect of the 
EXE ± oral agents/insulins in patients with HbA1c  10% are 
needed to fully clarify the role of this agent in the treatment 
of poorly managed type 2 DM. Additionally, long-term 
studies evaluating the efficacy and safety of EXE 2 µg SC 
once weekly in patients with type 2 DM and patients with 
insulin resistance without diabetes are needed.
Conclusions
EXE, a functional analog of human GLP-1, has been found 
to regulate glucose-dependent insulin secretion, to reduce 
postprandial hyperglycemia, to suppress inappropriately 
high glucagon secretions, to slow down gastric emptying 
and to reduce food intake/body weight. EXE at the dose of 
10 µg SC BID has proven to decrease HbA1c by 1.3 ± 0.1% 
and decrease body weight by up to 5.3 ± 0.8 kg at week 82. 
Nausea was the most frequently reported adverse event 
(.20%) especially in patients being treated with EXE 10 µg 
SC BID. As a result, EXE dose escalation from 5 µg SC BID 
for a month to 10 µg SC BID is recommended. While being 
treated with EXE, patients that experience severe abdominal 
pain with or without nausea/vomiting, should seek immediate 
medical attention to rule out hemorrhagic/necrotizing 
pancreatitis. EXE can be safely added to metformin therapy, 
sulfonylurea therapy or metformin and sulfonylurea therapy 
combination to effectively target glycemic goals in patients 
with type 2 DM. A new formulation of EXE 2 mg sustained 
release SC once weekly for the treatment of type 2 diabetes 
is being study. This new formulation has shown to reduce 
HbA1c by 1.9% and body weight by 3.7 kg at week 30. This 
formulation seems to share a similar tolerability profile that 
EXE SC BID with nausea and vomiting being the most 
commonly reported adverse events.
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